Define the source, EPA/DHA basis and oxidation plan before calling a gummy “omega-3.”
Sucotond USA coordinates non-confidential feasibility review for U.S. brands planning custom omega-3 gummies. The review connects source material, fatty-acid identity, oil or powder form, serving and label basis, gummy process, oxidation/sensory methods, package and time-point evidence before a commercial commitment.
This is a custom-project service page, not a claim that one stocked source, EPA/DHA level, oil, powder, emulsion, method, formula or shelf life fits every project.
Project Starting Point“Omega-3 oil” is not a complete product specification
A reviewable brief distinguishes the biological source and supplier material, the individual fatty acids and label quantities, the delivery format entering the gummy and the quality evidence attached to the final product.
Source identity
Fish, krill, microalgal and other sources are not interchangeable descriptions. Capture source organism/material, supplier, lot, processing context and applicable allergen review.
Fatty-acid identity
ALA, EPA and DHA are different omega-3 fatty acids. State the intended dietary ingredient, individual amounts, combined basis and serving instead of using “omega-3” alone.
Oil, powder or emulsion
Bulk oil, encapsulated powder and emulsion systems can differ in fatty-acid concentration, carrier, antioxidant, chemical form, moisture interaction and process behavior.
Oxidation and sensory evidence
Primary/secondary oxidation measures, calculated indices, volatile/sensory observations and shelf-life results answer different questions and can be matrix-sensitive.
Eight decisions that make an omega-3 gummy project reviewable
1. Source and supplier material
- Fish, algal, krill or other reviewed source
- Source species/organism and supplier identifier where applicable
- Lot, production form and identity/composition records
- Source-specific allergen and safety review owner
2. Fatty-acid and label target
- ALA, EPA, DHA and combined wording kept distinct
- EPA plus DHA—not only total oil
- Amount per serving and acceptable piece count
- Supplement Facts, source and claim approval responsibility
3. Material format and carrier
- Oil, powder, beadlet, emulsion or other reviewed form
- Fatty-acid concentration and chemical-form context
- Carrier, wall material, antioxidant and other excipients
- Storage, handling and supplier change controls
4. Gummy feasibility and sensory system
- Target load, piece weight and serving count
- Gelling, sweetener, acid, flavor, color and coating system
- Mixing, addition, temperature and hold-time questions
- Odor, taste, appearance and sample-to-scale acceptance
5. Fatty-acid and oxidation methods
- EPA/DHA composition method and reporting basis
- Primary, secondary or calculated oxidation question
- Sample preparation and flavored-gummy matrix suitability
- Laboratory, specification source, units and limitations
6. Contaminant and allergen scope
- Source- and market-specific risk assessment
- Applicable contaminant criteria and method ownership
- Major-allergen declaration and cross-contact review
- Supplier records versus finished-product verification
7. Package and stability plan
- Container, closure, count, headspace and protective assumptions
- Light, oxygen, moisture, temperature and distribution questions
- Formula/package/batch/time-point coverage
- Trend, excursion and shelf-life decision owners
8. Commercial and document scope
- Target market, volume stage and delivery point
- Component, batch, laboratory, package and stability records
- Disclosure and publication rights
- MOQ, timing and quote validity confirmed after review
Make every omega-3 field carry its own evidence question
The table is intentionally not prefilled with a source, EPA/DHA amount, oxidation limit or shelf life. Those values become publishable only when they belong to the approved project and evidence scope.
| Project field | Buyer input | Required confirmation before commitment |
|---|---|---|
| Source identity | Fish/algal/other direction and source constraints | Supplier, source organism/material, lot, processing form and identity/composition specification |
| Fatty-acid basis | ALA, EPA, DHA, combined amount and serving target | Individual/combined assay basis, units, serving, label and acceptance criteria |
| Material format | Oil, powder, emulsion or acceptable alternatives | Concentration, chemical-form context, carrier, antioxidant, storage and handling |
| Gummy system | Load, piece count, gelling/sweetener system and sensory direction | Approved formula, process feasibility, sample transfer, controls and change triggers |
| Quality methods | Fatty-acid, oxidation and contaminant evidence expected | Analyte, method, preparation, matrix suitability, units, time point and limitations |
| Label and allergen | Proposed source/amount/claim wording and market | Supplement Facts, ingredients, applicable allergen declaration, claims and artwork revision |
| Package and shelf life | Container, closure, count, storage wording and proposed date | Commercial formula/package, conditions, batches, time points, results, trend and decision |
| Commercial terms | Volume stage, delivery point and launch window | Materials, package, evidence scope, quantity, timing and current quote |
Connect the received source material to the labeled commercial lot
Supplier material
Source, lot, form, composition, carrier and component criteria.
Incoming decision
Identity/composition evidence, sampling and supplier qualification.
Approved formula
Serving, gummy system, label basis, package and controlled revision.
Commercial process
Handling, mixing, controls, master/batch records and deviations.
Finished evidence
Fatty acids, oxidation, contaminants and quality disposition.
Time and label
Package, storage, time points, effective artwork and distributed lot.
Use the product specification checklist to define acceptance fields, the laboratory report checklist to review method and result scope, the shelf-life evidence checklist to connect package and time points, and the label/artwork checklist to control source, amount and allergen wording.
NIH distinguishes ALA, EPA and DHA—and multiple supplement forms
NIH's Office of Dietary Supplements describes ALA, EPA and DHA as different omega-3 fatty acids and notes that supplements can use sources such as fish oil, krill oil, cod liver oil and algal oil. It also describes multiple chemical forms. That supports a buyer requirement to identify the source, material form and EPA plus DHA—not only total oil. It does not establish a Sucotond formulation, absorption result or health outcome.
Source, serving, dietary ingredient and other ingredients must reconcile
Label the actual project basis
FDA's dietary-supplement materials describe serving and dietary-ingredient declarations as well as source and other-ingredient labeling. For an oil powder or emulsion, the project file should reconcile the EPA/DHA basis with the source oil, carrier, wall material, antioxidant, flavor and other formula inputs.
Review allergens by source and formula
FDA identifies fish and Crustacean shellfish among major food allergens and provides guidance that includes dietary-supplement situations. The responsible firm should review the exact source ingredient, processing, other ingredients and label configuration rather than applying an unqualified allergen statement to every omega-3 project.
Market studies disagree, so use them to ask questions—not assign a failure rate
A Canadian/North American study tested 171 products and reported a substantial share above selected voluntary oxidation criteria. A later French-market study of 20 unflavored products reported that all sampled products met the voluntary criteria it applied. A multi-year U.S. study of 72 products reported differences associated with flavoring and formulation. These are different samples, markets, periods, delivery forms and analyses. Together they support a project-specific oxidation and method review; this evidence is not a universal industry failure rate and does not establish a Sucotond result.
Canada/North America study · French-market study · U.S. multi-year study
The final claim still needs a controlled manufacturing and quality file
FDA's dietary-supplement CGMP guide describes component identity and specifications, appropriate scientifically valid tests or examinations, finished-product specifications, packaging and label specifications, master/batch records and quality-control disposition. For an omega-3 gummy, those controls must connect to the selected material and the decision being made.
- Component: identify the received source material and define its fatty-acid/composition basis.
- Process: connect storage, handling, addition, mixing and commercial records to the identified batch.
- Method: define the analyte, preparation, matrix limitations, units, time point and acceptance criterion.
- Finished product: establish applicable fatty-acid, oxidation, contaminant and physical criteria and quality disposition.
- Package and label: reconcile the effective source/EPA/DHA wording, allergen statement, package and shelf-life support.
FDA Dietary Supplement CGMP Small Entity Compliance Guide
Keep sales, manufacturing, brand and evidence roles visible
Brooklyn project office
Sucotond USA coordinates non-confidential buyer inputs, commercial communication, evidence requests, project status and delivery planning. It does not select an oil source or approve a health/allergen claim for the brand.
Guangzhou production facility
The company identifies Sucotond (Guangzhou) Health Biotechnology Co., Ltd. as responsible for development, feasibility, production, in-process controls and batch records. Facility evidence and product evidence remain separate.
Brand / responsible firm
The brand defines the intended market, source, serving and claim basis, approves the formula/specification and obtains qualified ingredient-status, allergen, label, safety and substantiation review.
Ingredient supplier and laboratory
Supplier and laboratory records must match the exact material lot, sample, analyte, method and report. A COA or oxidation result does not automatically authorize public use or validate another batch.
Omega-3 gummy project questions
What information is needed before requesting an omega-3 gummy quote?
Define the intended source and supplier material, whether the target concerns ALA, EPA, DHA or a combination, the amount per serving and acceptable piece count, oil/powder/emulsion form, carrier and other ingredients, gummy and package direction, target market, evidence requirements and volume stage.
Is the total fish or algal oil amount the same as the EPA plus DHA amount?
No. Total source-oil or powder mass can include fatty acids and other material beyond EPA and DHA. Reconcile source material, assay basis, EPA amount, DHA amount, total omega-3 wording, serving and label units instead of using one number for all of them.
Do peroxide, p-anisidine and TOTOX answer the same oxidation question?
No. They describe different measurements or calculations. State the applicable specification source, method, sample preparation, units, flavor/matrix limitations, time point and acceptance decision. One result or calculated value is not a universal product-quality conclusion.
Can a published market study predict the quality of a Sucotond omega-3 gummy?
No. Published studies belong to their sampled products, markets, years, delivery forms, flavor systems, methods and voluntary comparison criteria. Their findings differ and do not establish a Sucotond result or a universal industry failure rate.
What evidence can a brand request for a commercial omega-3 gummy project?
Define supplier and lot identity/composition records, source and applicable allergen review, approved formula and product specification, sample approval, master and batch records, agreed fatty-acid, oxidation and contaminant reports, package and label revision, stability evidence and quality disposition. Availability and disclosure rights depend on the project and document owners.
Request an omega-3 gummy feasibility map
Share the source/material status, intended EPA/DHA basis, serving, gummy system, package, market, volume stage, evidence expectations and timing. The review identifies open questions; it is not a formula, quote, method, result or production commitment.
Brooklyn, NY 11214